Stoke Therapeutics, Inc. (STOK) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Stoke Therapeutics, Inc. (NASDAQ:STOK) is held by 152 institutional firms.

• These investors collectively held 124.6% of the company's total shares outstanding in September 2025, up from 119.9% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 4.48%, with a year-over-year an increase of 28.81% in the count of filers.
• Of these 152 institutional investors, 81 increased their holdings in Stoke Therapeutics, while 48 of them reduced positions, and 23 investors maintained their exposure.
• This class of investors increased its holdings in Stoke Therapeutics to 68.30Mn shares for the 13F-cycle ending September 2025, up by 2.93Mn shares quarter on quarter, and up 10.14Mn shares year over year.
• FMR LLC's holding of 6.87Mn shares as of September 30, 2025 makes it the primary institutional investor in Stoke Therapeutics, owning 12.53% of the stock.
• Among the most significant buyers of Stoke Therapeutics during September 2025 were BVF INC/IL (1.66Mn), Point72 Asset Management, L.P. (1.16Mn), ROYAL BANK OF CANADA (771.72K), WELLINGTON MANAGEMENT GROUP LLP (600.69K), Caption Management, LLC (560.00K).
• Leading sellers of Stoke Therapeutics stock in September 2025 included MARSHALL WACE, LLP (1.53Mn), Skorpios Trust (1.00Mn), FMR LLC (547.92K), Checkpoint Capital L.P. (518.67K), DAFNA Capital Management LLC (332.18K).
• The top 10 institutional holders of Stoke Therapeutics for the quarter ending September 2025 included FMR LLC (6.87Mn), BlackRock, Inc. (5.99Mn), Lynx1 Capital Management LP (5.40Mn), RTW INVESTMENTS, LP (5.12Mn), BAKER BROS. ADVISORS LP (4.63Mn), Redmile Group, LLC (4.18Mn), MORGAN STANLEY (3.54Mn), TORONTO DOMINION BANK (3.17Mn), VANGUARD GROUP INC (3.16Mn), Skorpios Trust (2.26Mn).